Maria Stamelou  (Μαρία Σταμέλου)
Maria Stamelou (Μαρία Σταμέλου)
Prof. of Neurology, Head of Movement Disorders Dept, Hygeia Hospital, Athens, Greece
Bestätigte E-Mail-Adresse bei hygeia.gr - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
GU Höglinger, G Respondek, M Stamelou, C Kurz, KA Josephs, AE Lang, ...
Movement Disorders 32 (6), 853-864, 2017
8112017
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
GU Höglinger, NM Melhem, DW Dickson, PMA Sleiman, LS Wang, L Klei, ...
Nature genetics 43 (7), 699-705, 2011
4672011
Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society
KP Bhatia, P Bain, N Bajaj, RJ Elble, M Hallett, ED Louis, J Raethjen, ...
Movement Disorders 33 (1), 75-87, 2018
4392018
Dopaminergic reward system: a short integrative review
O Arias-Carrión, M Stamelou, E Murillo-Rodríguez, ...
International archives of medicine 3 (1), 1-6, 2010
4082010
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
JA Obeso, M Stamelou, CG Goetz, W Poewe, AE Lang, D Weintraub, ...
Movement Disorders 32 (9), 1264-1310, 2017
4052017
The non-motor syndrome of primary dystonia: clinical and pathophysiological implications
M Stamelou, MJ Edwards, M Hallett, KP Bhatia
Brain 135 (6), 1668-1681, 2012
2592012
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases
G Respondek, M Stamelou, C Kurz, LW Ferguson, A Rajput, WZ Chiu, ...
Movement Disorders 29 (14), 1758-1766, 2014
2392014
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.
DST Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, T Investigators.
Movement Disorders Journal 29 (4), 470-478, 2014
227*2014
Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis
G Charlesworth, V Plagnol, KM Holmström, J Bras, UM Sheerin, E Preza, ...
The American Journal of Human Genetics 91 (6), 1041-1050, 2012
2162012
Reward pays the cost of noise reduction in motor and cognitive control
SG Manohar, TTJ Chong, MAJ Apps, A Batla, M Stamelou, PR Jarman, ...
Current Biology 25 (13), 1707-1716, 2015
2112015
AFQ056 treatment of levodopa‐induced dyskinesias: results of 2 randomized controlled trials
D Berg, J Godau, C Trenkwalder, K Eggert, II Csoti, A Storch, H Huber, ...
Movement Disorders 26 (7), 1243-1250, 2011
1712011
PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine
AR Gardiner, KP Bhatia, M Stamelou, RC Dale, MA Kurian, SA Schneider, ...
Neurology 79 (21), 2115-2121, 2012
1662012
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers
NE Mencacci, IU Isaias, MM Reich, C Ganos, V Plagnol, JM Polke, J Bras, ...
Brain 137 (9), 2480-2492, 2014
1602014
Short‐term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo‐controlled trial
M Stamelou, A Reuss, U Pilatus, J Magerkurth, P Niklowitz, KM Eggert, ...
Movement disorders: official journal of the Movement Disorder Society 23 (7 …, 2008
1592008
The expanding universe of disorders of the basal ganglia
JA Obeso, MC Rodriguez-Oroz, M Stamelou, KP Bhatia, DJ Burn
The Lancet 384 (9942), 523-531, 2014
1582014
Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications
K Eggert, C Schrader, M Hahn, M Stamelou, A Rüssmann, R Dengler, ...
Clinical neuropharmacology 31 (3), 151-166, 2008
1452008
Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?
JL Whitwell, GU Höglinger, A Antonini, Y Bordelon, AL Boxer, C Colosimo, ...
Movement Disorders 32 (7), 955-971, 2017
1202017
The clinical and genetic heterogeneity of paroxysmal dyskinesias
AR Gardiner, F Jaffer, RC Dale, R Labrum, R Erro, E Meyer, ...
Brain 138 (12), 3567-3580, 2015
1202015
Rational therapeutic approaches to progressive supranuclear palsy
M Stamelou, R de Silva, O Arias-Carrión, E Boura, M Höllerhage, ...
Brain 133 (6), 1578-1590, 2010
1152010
The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort
K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ...
Annals of clinical and translational neurology 5 (12), 1460-1477, 2018
1132018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20